SCHEMBL29598682

SCHEMBL29598682

COc1c(C(=O)CC(=O)c2ccc3c(c2)OCO3)ccc2occc12

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 4/20 0.70
CYP1B1 Q16678 4/20 0.70
CYP1A2 P05177 2/20 0.65
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CTNNB1 P35222 5/20 0.47
WNT3A P56704 5/20 0.47
ABCB1 P08183 1/20 0.45
MAPT P10636 1/20 0.44
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HPGD P15428 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NQO1 P15559 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ovalitenone SCHEMBL29598773 0.82 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL29598875 0.80 CYP1A1 (0.57) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL900826 0.79 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL29664148 0.79 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL2237626 0.74 MEN1 (0.76) MEN1KMT2ACTNNB1WNT3AMAPT
SCHEMBL29458253 0.74 MEN1 (0.76) MEN1KMT2ACTNNB1WNT3AMAPT
SCHEMBL26624014 0.74 KMT2A (0.72) MEN1KMT2ACTNNB1WNT3AMAPT
SCHEMBL13516462 0.72 MEN1 (1.00) MEN1KMT2ACTNNB1WNT3ANPC1
SCHEMBL2045384 0.71 CYP1A1 (0.63) CYP1A1CYP1B1CYP1A2ABCB1MAPT
SCHEMBL17055815 0.70 MEN1 (0.74) MEN1KMT2ACTNNB1WNT3ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12610971-B2 Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof TerViva BioEnergy, Inc. (US) 2026-04-28 US claimed
US-12610971-B2 Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof TerViva BioEnergy, Inc. (US) 2026-04-28 US disclosed
US-12052994-B2 Methods for controlling black sigatoka in bananas using pongamia oil and formulations thereof Terviva, Inc. (US) 2024-08-06 US disclosed
CN-116036646-A Extraction process and extraction device for smilax glabra rhizome active ingredient capable of inhibiting xanthine oxidase 湖州市食品药品检验研究院(湖州市药品和医疗器械不良反应监测中心、湖州市医疗器械监督检验中心、湖州市食品认证审评和粮油质量监测中心) 2023-05-02 CN disclosed
US-20220369662-A1 EDIBLE PONGAMIA COMPOSITIONS, AND METHODS OF PREPARING AND USING THEREOF Terviva, Inc. (US) 2022-11-24 US disclosed
EP-4037491-A1 EDIBLE PONGAMIA COMPOSITIONS, AND METHODS OF PREPARING AND USING THEREOF TerViva, Inc. (US) 2022-08-10 EP disclosed
US-20220125059-A1 METHODS FOR CONTROLLING BLACK SIGATOKA IN BANANAS USING PONGAMIA OIL AND FORMULATIONS THEREOF Terviva, Inc. (US) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125059-A1 METHODS FOR CONTROLLING BLACK SIGATOKA IN BANANAS USING PONGAMIA OIL AND FORMULATIONS THEREOF LIPA, SIGLEC7, AMY1A CYP1A1 3611/4885CYP1B1 3816/4885CYP1A2 2668/4885
US-12610971-B2 Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof DEK, DGKG, SRMS CYP1A1 2801/4885CYP1B1 3735/4885CYP1A2 2420/4885
US-12052994-B2 Methods for controlling black sigatoka in bananas using pongamia oil and formulations thereof LIPA, SIGLEC7, AMY1A CYP1A1 3611/4885CYP1B1 3816/4885CYP1A2 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.